Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
117 hedge funds and large institutions have $85.2M invested in Sanofi Contingent Value Rights in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 35 reducing their positions, and 14 closing their positions.
0% more funds holding
Funds holding: 117 → 117 (0)
38% less capital inflows, than outflows
Capital inflows: $3.82M | Capital outflows: $6.18M
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
63% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.4M |
| 2 |
LCM
Lonestar Capital Management
San Francisco,
California
|
+$888K |
| 3 |
CPM
Chesapeake Partners Management
Baltimore,
Maryland
|
+$332K |
| 4 |
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$69.5K |
| 5 |
Catalyst Capital Advisors
Huntington,
New York
|
+$46.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
-$3.02M |
| 2 |
NM
Newtyn Management
New York
|
-$822K |
| 3 |
BTG Pactual Global Asset Management
Hamilton,
Bermuda
|
-$372K |
| 4 |
MCM
Mason Capital Management
New York
|
-$278K |
| 5 |
Whitebox Advisors
Minneapolis,
Minnesota
|
-$250K |
GCVRZ Hedge Fund Activity: Q4 2014 in Review
117 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2014, worth a combined $85.2M — up 64% from $52M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GCVRZ and 8 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 13 added.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.4M. The largest seller was Gruss Capital Management, cutting an estimated $3.02M.
- 117 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $85.2M of Sanofi Contingent Value Rights stock for Q4 2014, up 64% quarter-over-quarter.
- 8 funds opened new Sanofi Contingent Value Rights positions in Q4 2014 and 14 closed out, a net change of -6 holders.
- The largest Sanofi Contingent Value Rights buyer in Q4 2014 was Oxford Asset Management, an estimated $2.4M added.
- The largest Sanofi Contingent Value Rights seller in Q4 2014 was Gruss Capital Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2014.